SynthesisFrontiers in oncology2026
Oral selective estrogen receptor degraders in ER+/HER2- breast cancer: a systematic review with pooled analysis of metastatic randomized trials and narrative synthesis of adjuvant evidence.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral selective estrogen receptor degraders (SERDs) have become a key therapeutic option for hormone receptor-positive, HER2-negative advanced breast cancer. The recent presentation of lidERA-the first positive adjuvant Phase III trial of any oral SERD-necessitates a comprehensive evidence synthesis spanning both early and advanced disease settings, beyond the scope of existing meta-analyses confined to metastatic disease. Methods: This review was prospectively registered (PROSPERO CRD420261358420). We searched PubMed, Cochrane CENTRAL, and conference abstract archives (SABCS, ESMO, ASCO; 2020-2026) for Phase II/III randomized controlled trials comparing oral SERDs (giredestrant, imlunestrant, elacestrant, camizestrant, vepdegestrant, amcenestrant) with standard endocrine therapy in ER-positive, HER2-negative breast cancer. Progression-free survival hazard ratios in the metastatic setting were pooled using random-effects models. Prespecified sensitivity analyses included Bayesian re-analysis. Results: Ten randomized controlled trials met inclusion criteria (one adjuvant, n = 4,170; nine metastatic). Giredestrant significantly improved invasive disease-free survival in the adjuvant lidERA trial (HR 0.70; 95% CI 0.57-0.87; Conclusions: Oral SERDs confer a consistent progression-free survival benefit in advanced breast cancer, with the most robust and consistent effect in Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php, identifier CRD420261358420.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.